Spots Global Cancer Trial Database for neupogen
Every month we try and update this database with for neupogen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF) | NCT00776165 | Chemotherapy-In... | Recombinant Hum... Neupogen | 18 Years - | Shantha Biotechnics Limited | |
| Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | NCT01523678 | Ovarian Cancer Endometrial Can... Uterine Cervica... | Filgrastim Paclitaxel Carboplatin | 18 Years - | Belgian Gynaecological Oncology Group | |
| Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | NCT00943943 | Acute Myelogeno... Leukemia | G-CSF Plerixafor Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia | NCT00446173 | Leukemia | Busulfan Cyclophosphamid... G-CSF GM-CSF | 21 Years - 65 Years | M.D. Anderson Cancer Center | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | NCT00822770 | Stem Cell Trans... Leukemia | Plerixafor Filgrastim Fludarabine Busulfan Allogeneic bloo... ATG (Thymoglobu... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | NCT00822770 | Stem Cell Trans... Leukemia | Plerixafor Filgrastim Fludarabine Busulfan Allogeneic bloo... ATG (Thymoglobu... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib | NCT02489500 | AL Amyloidosis | Bortezomib Melphalan Neupogen Stem Cell Colle... Stem cell infus... | 18 Years - | Boston Medical Center | |
| Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center | |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | NCT01875237 | Leukemia Myeloma Myeloproliferat... | Fludarabine Melphalan Alemtuzumab Stem Cell infus... Tacrolimus Mini Methotrexa... G-CSF Donor Lymphocyt... AP1903 Methylprednisol... Questionnaire | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years | NCT00254410 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Mitoxantrone Rituximab Filgrastim | - 70 Years | M.D. Anderson Cancer Center | |
| Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen | NCT00074165 | Brain and Centr... Drug/Agent Toxi... Lymphoma Thrombocytopeni... | Rituxan Cyclophosphamid... Etoposide Etoposide phosp... Carboplatin Sodium thiosulf... Neupogen Neulasta Cytarabine | 18 Months - 75 Years | OHSU Knight Cancer Institute | |
| Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer | NCT00237575 | Bladder Cancer | gemcitabine cisplatin sargramostim filgrastim | 18 Years - | University of Kentucky | |
| Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia | NCT02816112 | Early Stage Bre... | Ciprofloxacin Neupogen | 19 Years - | Ottawa Hospital Research Institute | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | NCT01538472 | Lymphoma | Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00402558 | Myelodysplastic... Leukemia | Thymoglobulin Busulfan Fludarabine Alloreactive NK... G-CSF Tacrolimus Methotrexate Interleukin-2 | - 70 Years | M.D. Anderson Cancer Center | |
| Study of Bortezomib in Combination With Cyclophosphamide and Rituximab | NCT00958256 | Mantle Cell Lym... Lymphoma | Bortezomib Rituximab Cyclophosphamid... Mesna G-CSF | 18 Years - 85 Years | M.D. Anderson Cancer Center | |
| Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | NCT01538472 | Lymphoma | Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | NCT01572662 | Leukemia Acute Myeloid L... Acute Lymphocyt... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Non-Hodgkins Ly... Hodgkins Lympho... Multiple Myelom... Myelodysplastic... | Fludarabine mon... Busulfan Stem Cell Infus... Tacrolimus Methotrexate G-CSF | 5 Years - 75 Years | M.D. Anderson Cancer Center | |
| Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer | NCT00237575 | Bladder Cancer | gemcitabine cisplatin sargramostim filgrastim | 18 Years - | University of Kentucky | |
| Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | NCT00943943 | Acute Myelogeno... Leukemia | G-CSF Plerixafor Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00402558 | Myelodysplastic... Leukemia | Thymoglobulin Busulfan Fludarabine Alloreactive NK... G-CSF Tacrolimus Methotrexate Interleukin-2 | - 70 Years | M.D. Anderson Cancer Center | |
| Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS | NCT00520468 | Myelodysplastic... | Erythropoietin Cyclosporin A G-CSF Prednisone | - | M.D. Anderson Cancer Center | |
| Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers | NCT02682953 | Bone Marrow Tra... Hematopoietic S... Multiple Myelom... Lymphoma | Neupogen Hyperbaric oxyg... Plerixafor | 21 Years - | University of Maryland, Baltimore | |
| Tandem Auto-Allo Transplant for Lymphoma | NCT01181271 | Diffuse, Large ... Lymphoma, Low-G... T-Cell Lymphoma Mantle-Cell Lym... Hodgkin's Lymph... Chronic Lymphoc... Lymphoma, Small... | Busulfan (condi... Etoposide (cond... Cyclophosphamid... Mesna (prior to... autologous (aut... Neupogen Fludarabine (co... Busulfan (condi... non-myeloablati... Tacrolimus Sirolimus Methotrexate | 18 Years - 75 Years | Massachusetts General Hospital | |
| A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia | NCT02816164 | Early Stage Bre... | Neupogen | 19 Years - | Ottawa Hospital Research Institute | |
| Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas | NCT01329900 | Lymphoma | Ofatumumab Ifosfamide Etoposide Mesna G-CSF Stem Cell Colle... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma | NCT01237951 | Myeloma | Palifermin Dexamethasone Gemcitabine Busulfan Melphalan Stem Cell Trans... G-CSF | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
